Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nivolumab
Nivolumab is a substance that helps the immune system recognize and attack certain cancers.
Tebentafusp
Tebentafusp is an immunotherapy that redirects T cells to target and kill tumor cells in a type of eye melanoma.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Brenetafusp

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Graz
Dermatology
Graz, Austria
Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH
Dermatology and Allergology
Salzburg, Austria
Noe LGA Gesundheit Region Mitte GmbH
Department of Dermatology
Sankt Pölten, Austria

Sponsor: Immunocore Limited
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.